[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

OA10157A - Antimalarial drug - Google Patents

Antimalarial drug Download PDF

Info

Publication number
OA10157A
OA10157A OA60662A OA60662A OA10157A OA 10157 A OA10157 A OA 10157A OA 60662 A OA60662 A OA 60662A OA 60662 A OA60662 A OA 60662A OA 10157 A OA10157 A OA 10157A
Authority
OA
OAPI
Prior art keywords
antimalarial drug
quinine
sulfated
crds
antimalarial
Prior art date
Application number
OA60662A
Other languages
English (en)
Inventor
Ivan Havlik
Yutaro Kaneko
Tohru Mimura
Chihara Goro
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of OA10157A publication Critical patent/OA10157A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
OA60662A 1993-09-20 1995-05-19 Antimalarial drug OA10157A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23329693 1993-09-20

Publications (1)

Publication Number Publication Date
OA10157A true OA10157A (en) 1996-12-18

Family

ID=16952886

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60662A OA10157A (en) 1993-09-20 1995-05-19 Antimalarial drug

Country Status (9)

Country Link
US (1) US5780452A (ja)
EP (1) EP0676206B1 (ja)
JP (1) JP3718849B2 (ja)
CA (1) CA2148607A1 (ja)
CZ (1) CZ128095A3 (ja)
DE (1) DE69422496T2 (ja)
ES (1) ES2142407T3 (ja)
OA (1) OA10157A (ja)
WO (1) WO1995008334A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414320C (en) 2000-06-30 2008-04-01 Polydex Pharmaceuticals Limited Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
EP1552823A3 (en) * 2000-06-30 2005-09-21 Polydex Pharmaceuticals Limited Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
EP1329452A1 (en) * 2000-10-20 2003-07-23 Ajinomoto Co., Inc. Medicinal compositions, dose and method for treating malaria
FR2998176B1 (fr) * 2012-11-16 2015-01-16 Univ Blaise Pascal Clermont Ii Composition de polysaccharide sulfate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1129148B (de) * 1960-10-19 1962-05-10 Egyt Gyogyszervegyeszeti Gyar Verfahren zur Herstellung von Heparin-Derivaten zytostatisch wirkender Stoffe
GB1227830A (ja) * 1968-07-18 1971-04-07
US4197643A (en) * 1978-03-14 1980-04-15 University Of Connecticut Orthodontic appliance of titanium alloy
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4807177A (en) * 1986-06-06 1989-02-21 Ward Richard J Multiple format hand held label printer
US5512672A (en) * 1988-07-07 1996-04-30 Ajinomoto Co., Inc. Curdlan sulfate
JPH0725802B2 (ja) * 1988-11-28 1995-03-22 味の素株式会社 カードランまたはレンチナンの硫酸エステルまたはその塩の製造方法
JPH03218317A (ja) * 1988-12-06 1991-09-25 Japan Found Cancer Res 抗レトロウイルス剤
JP2772813B2 (ja) * 1989-03-03 1998-07-09 サッポロビール株式会社 抗ウイルス作用と免疫賦活作用を有する組成物
SE9003181D0 (sv) * 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction

Also Published As

Publication number Publication date
CZ128095A3 (en) 1995-10-18
EP0676206A4 (ja) 1995-10-25
CA2148607A1 (en) 1995-03-30
EP0676206B1 (en) 2000-01-05
EP0676206A1 (en) 1995-10-11
DE69422496T2 (de) 2002-07-11
WO1995008334A1 (fr) 1995-03-30
JP3718849B2 (ja) 2005-11-24
ES2142407T3 (es) 2000-04-16
DE69422496D1 (de) 2000-02-10
US5780452A (en) 1998-07-14

Similar Documents

Publication Publication Date Title
US5292772A (en) Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome
Rieckmann et al. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
RU95121731A (ru) Применение рилузола для лечения нейро-спида и способ получения лекарственного средства
US4425363A (en) Treatment of tardive dyskinesia in mammals
Wilairatana et al. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.
OA10157A (en) Antimalarial drug
US5011841A (en) Treatment of depression
Rieckmann et al. Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand
US5817642A (en) Clearing of atherosclerosis
JPH0352815A (ja) 血管内血液凝固症候群の治療剤
NZ217431A (en) Synergistically antimalarial combination preparations comprising an iron(iii) chelating agent and a schizontocide
US8304440B2 (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
JP2003519088A (ja) Hiv感染患者の治療および予防のためのgssgレダクターゼの使用
US4680311A (en) Method for the treatment of systemic mycosis
US5486535A (en) Method for treating toxoplasmosis
US5886000A (en) Anti-HIV agent
WO1995029683A1 (en) Pharmaceutical composition comprising hyaluronic acid for the clearing of arteriosclerosis
CA2356453A1 (en) Anti-hiv infection agents and method for treating hiv infection
Walker et al. Modified Dosing Schedule Efficacy of Fosmidomycin and Clindamycin Against Murine Malaria Plasmodium berghei
IE55181B1 (en) Treatment of minimal brain dysfunction(mbd)
CA1307740C (en) Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus
US3636208A (en) Method for treating malaria